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ABSTRACT
Feline oral squamous cell carcinomas (FOSCC) are highly aggressive neoplasms 
with short survival times despite multimodal treatment. FOSCC are similar to 
squamous cell carcinomas of the head and neck (SCCHN) in humans, which also 
present therapeutic challenges. The current study was undertaken to identify novel 
chemotherapeutics using FOSCC cell lines. A high throughput drug screen using 1,952 
drugs was performed to identify chemotherapeutics for further investigation. Two of 
the drugs identified in the drug screen, actinomycin D and methotrexate, and two 
drugs with similar molecular targets to drugs found to be efficacious in the screening, 
dinaciclib and flavopiridol, were selected for further investigation. Drug inhibition 
profiles were generated for each drug and cell line using an MTS assay. In addition, 
the effects of the drugs of interest on cell cycle progression were analyzed via a 
propidium iodide DNA labeling assay. Changes in caspase-3/7 activity after treatment 
with each drug were also determined. The findings demonstrated effectiveness of 
the drugs at nanomolar concentrations with sensitivity varying across cell lines. 
With all of the drugs except for actinomycin D, evidence for G1 arrest was found. 
Dinaciclib and flavopiridol were demonstrated to induce apoptosis. The results of the 
study suggest that the selected drugs are potential candidates for developing novel 
chemotherapeutic approaches to FOSCC. Through these studies, novel therapeutic 
strategies for the treatment of FOSCC can be developed to provide better care for 
affected cats which can also serve as proof of concept studies to inform translational 
studies in SCCHN in humans.
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INTRODUCTION
Head and neck cancer in humans comprise the sixth 
most common cancer worldwide, and approximately 
90% are classified as squamous cell carcinomas of the 
head and neck (SCCHN) [1, 2]. Although the one-year 
survival time is approximately 83% for oral cavity and 
pharyngeal tumors, the five-year survival time is only 
60% [3]. Poor prognostic factors include bone invasion, 
recurrent disease, and metastasis [4]. Advanced disease 
is present in approximately half of patients at the time 
of diagnosis [5]. Human papillomavirus DNA has been 
detected in 3.9% of oral cavity cancer biopsies and 18.3% 
of cancers in the oropharynx in humans [6]. Thus, to date, 
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the vast majority of SCCHN tumors are not associated 
with papillomavirus infection. 
Currently, a multi-model therapeutic approach 
is used for SCCHN including chemotherapy, radiation 
therapy, and surgical excision [3]. Chemotherapeutics used 
for head and neck cancer include the following: cisplatin, 
paclitaxel, carboplatin, 5-fluorouracil, mitomycin-C, 
cetuximab, and methotrexate [7, 8]. Analysis of the 
Cetuximab Plus Radiotherapy Versus Cisplatin Plus 
Radiotherapy in Locally Advanced Head and Neck 
Cancer Trial suggested that p16-positive oropharyngeal 
cancer may be more effectively treated with cisplatin than 
cetuximab in conjunction with radiotherapy; however, 
more studies are needed due to limitations of this study 
such as the small sample size [9]. The clinical trial did 
not specifically address epidermal growth factor receptor 
(EGFR) expression; however, EGFR expression is 
inversely related to p16 expression as well as inversely 
related to induction chemotherapy response and disease-
specific survival [10]. Initial studies indicated the 
potential use of a cetuximab plus docetaxel, cisplatin, 
and 5-fluorouracil regimen followed by intensity-
modulated radiotherapy for laryngeal and hypopharyngeal 
squamous cell carcinoma [11]. A regimen consisting of 
methotrexate, leucovorin, 5-fluorouracil, and cisplatin 
has been demonstrated to improve survival in patients 
with metastatic or recurrent head and neck cancer [12]. 
Methotrexate as a single agent has been considered the 
standard treatment for many patients with advanced, 
recurrent, or metastatic SCCHN [8]. Methotrexate is one 
of the most commonly used agents for palliative care in 
patients with recurrent SCCHN with a response rate of 
8–50% and serves as the standard for comparison in phase 
III studies [13]. Methotrexate may also be beneficial as 
a single agent for the treatment of verrucous carcinoma, 
a non-metastatic variant of well-differentiated squamous 
cell carcinoma [14]. Leucovorin can be combined with 
methotrexate to reduce severe systemic toxicity with some 
protocols [15]. A phase II comparison study, however, 
demonstrated that concurrent chemoradiotherapy using 
docetaxel, cisplatin, and 5-fluorouracil had an overall 
greater response rate and greater complete pathological 
response in comparison to concurrent chemoradiotherapy 
with cisplatin, 5-fluorouracil, methotrexate, and leucovorin 
in SCCHN patients with locally advance disease [16].
There are many similarities between feline oral 
squamous cell carcinoma (FOSCC) in cats and SCCHN 
in humans which has led to the proposal that FOSCC 
may serve as a spontaneous model for SCCHN [4]. Oral 
cancers represent approximately 10% of all diagnosed feline 
neoplasms with FOSCC accounting for approximately 60% 
of all oral cancers in cats [17]. The etiological cause of feline 
oral FOSCC has not been fully elucidated. Epidemiological 
surveys have identified several potential environmental 
risk factors including use of flea collars, consumption of 
a high canned food diet, and consumption of canned tuna; 
incidence of FOSCC was also increased with household 
environmental tobacco smoke exposure but failed to achieve 
statistical significance [18]. Exposure to environmental 
risk factors may be facilitated in part by the grooming 
behavior of cats, potentially increasing the oral dose of 
environmental carcinogens [17]. These studies, however, 
are both limited in scope and design. Further investigation 
will be necessary to demonstrate a causal relationship 
between such factors and the development of FOSCC and 
to explore other factors. Feline papillomaviruses 1 and 4, 
the only feline papillomaviruses known to infect oral tissue, 
are not frequently present in FOSCC lesions suggesting 
that, similar to SCCHN, papillomavirus infection is not a 
common cause of FOSCC [19]. 
FOSCC, clinically, is an aggressive neoplasia 
that is locally invasive [20]. Patients with FOSCC often 
present with advanced local disease [21]. In late stages 
of the disease, FOSCC can invade into local bone tissue 
depending on the site of tumor origin and metastasize to 
regional lymph nodes [4]. Though regional and distant 
metastasis have been reported, patients typically do not 
present with or develop detectable metastasis due to death 
resulting from complications associated with the primary 
tumor [22]. Prognosis for cats diagnosed with FOSCC is 
poor; the reported median survival time after presentation 
is less than two months without treatment [21]. When 
treatment is pursued, median survival time remains poor 
ranging from two to ten months regardless of treatment 
modality pursued [22]. After diagnosis, the one year 
survival rate for FOSCC is less than 10% [20]. Despite 
multiple therapeutic options, such as radiation therapy, 
chemotherapeutics, and surgery, significant progress in 
increasing patient survival has been limited [22]. To date, 
the use of chemotherapy as a single modality of treatment 
for FOSCC has had limited demonstrated efficacy and has 
not been shown to be beneficial as an adjunctive therapy 
[23]. Toceranib was well tolerated in the majority of cats 
when treating for FOSCC with low-grade gastrointestinal 
side effects most commonly reported; however, 
survival was not assessed due to lack of data, protocol 
standardization, and wide variety of concurrent treatments 
[24]. Thus, it remains unclear if the use of toceranib is truly 
beneficial for the treatment of FOSCC. Overall, similarities 
in environmental exposures, in addition to similarities in 
tumor aggressiveness and difficulty in treatment, may 
allow spontaneous FOSCC in cats to provide insight into 
non-papillomavirus-induced SCCHN in humans and assist 
in translational studies for novel therapies [25].
Novel chemotherapeutic options for feline FOSCC 
is the focus of this study due to the relatively poor 
response to current treatments, as well as its potential role 
as a model for SCCHN. FOSCC has been demonstrated 
to express epidermal growth factor receptor which may 
serve as a potential target for future therapeutics [26]. 
Similarly, cyclooxygenase (COX) 1 and 2 have been 
demonstrated to be expressed in FOSCC [27]. COX 
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inhibitors may be beneficial as adjunctive therapeutics as 
seen when meloxicam was combined with zolderonic acid 
and piroxicam was combined with masitinib, a receptor 
tyrosine kinase inhibitor [28, 29].  FOSCC was responsive 
to treatment with etanidazole along with radiation therapy, 
but the mean survival time remained below four months 
[30]. Ideally, a novel therapeutic would be cytotoxic to 
neoplastic cells, increase the radiosensitivity of neoplastic 
cells, and target putative stem cell fractions. No such drug 
has been demonstrated to fulfill these criteria for FOSCC 
based on the current literature available.
The current study sought to gain insight into 
novel therapeutic options for FOSCC focusing on small 
molecules that may be repurposed. A high throughput 
drug screen (HTS) was performed to identify compounds 
with potential use as a chemotherapeutic for FOSCC 
using three established FOSCC (kindly provided by Dr. 
Thomas Rosol at The Ohio State University) as well as 
feline fibroblasts derived from normal skin tissue as a 
representative for normal tissue [31–33]. Interestingly, 
the FOSCC cell lines were not susceptible to many of the 
drugs, but a few drugs warranted further investigation. 
These drugs included actinomycin D, methotrexate, and 
multiple kinase inhibitors [36–38]. The present study 
demonstrates that actinomycin D, methotrexate, dinaciclib 
and flavopiridol are effective against FOSCC in vitro 
while nontoxic to normal fibroblasts. These drugs are good 
candidates for future clinical trials in cats with FOSCC 
and provide insights for potential treatment options for 
SCCHN. 
RESULTS AND DISCUSSION
Identification of candidate drugs for treatment 
of FOSCC 
The HTS of the collection of 1,952 compounds 
from Prestwick, NCI Oncology, and GSK Kinase libraries 
was performed at 1 mM of each drug. A concentration of 
1 μM was selected to screen for strong candidate drugs as 
concentrations used for hit discovery with drug screening 
assays range frequently from 1–10 μM [34]. Candidate 
drugs were selected from the pool applying a cutoff of 
>25% inhibition in at least one of the FOSCC cell lines, 
and <60% inhibition in control fibroblasts. Compounds 
of unknown mechanisms of action were excluded, as 
well as those sharing >80% similarity in structure to 
another compound, yielding 60 compounds for further 
investigation in a dose response assay setting.  Drugs 
associated with altering the microenvironment, such as 
non-steroidal anti-inflammatory drugs, were excluded as 
cell culture does not allow evaluation of such effects [35]. 
Additional drugs with similar targets from the LOPAC 
library were included for the dose response assay. 
From the total of 60 compounds selected for 
dose response assay, actinomycin D, methotrexate, 
GW779439X, and GW778894X had an IC50 of less than 
100 nM and were potent inhibitors against all three FOSCC 
cell lines and selected for further study. Actinomycin D 
inhibits RNA transcription by binding double-stranded 
DNA at specific locations. [36]. Methotrexate is a 
dihydrofolate reductase inhibitor, though additional effects 
such as causing epigenetic modifications have been 
reported. The potential role for methotrexate for FOSCC is 
further supported by its use for SCCHN [13]. GW779439X 
and GW778894X are CDK2/CDK4 inhibitors that 
are under research by GlaxoSmithKline. A recently 
published kinome profiling data set, however, suggests 
that GW779439X may inhibit multiple other kinases in 
addition to CDK2/CDK4 and may be quite promiscuous 
with multiple off-target effects [37]. Due to the minimal 
availability of GW779439X and GW778894X, two other 
CDK inhibitors with similar mechanisms of action were 
chosen for further study: dinaciclib (Merck, Kenilworth, 
NJ) and flavopiridol (Sanofi, Bridgewater, NJ).  Dinaciclib 
is a cyclin-dependent kinase (CDK) inhibitor targeting 
CDK1, CDK2, CDK5, and CDK9 [38]. Dinaciclib may 
also act as a bromodomain inhibitor [39]. Flavopiridol acts 
most strongly on CDK1, CDK2, CDK4, CDK6, and CDK7 
[40]. Many small molecules have promiscuous effects, 
as evidenced by kinome profiling data, so it is difficult 
to exclude that dinaciclib and flavopiridol may have an 
effect on FOSCC through additional pathways [37]. Of 
the four drugs selected for further study, only methotrexate 
is currently reported for the treatment of SCCHN to the 
authors’ knowledge; thus, the other three drugs may be of 
translational value [13]. Additionally, the identification of 
methotrexate in the HTS may suggest that the other drugs 
identified via the HTS may be useful in SCCHN, though 
more research would be needed to validate this claim.
All three FOSCC cell lines were confirmed 
to be sensitive to actinomycin D, dinaciclib, 
flavopiridol, and methotrexate
Dose-response curves were performed to confirm the 
effectiveness of the chosen drugs to inhibit the growth of 
SCCF1, SCCF2, and SCCF3. IC50 values for actinomycin D, 
dinaciclib, flavopiridol, and methotrexate were extrapolated 
from the dose-response curves for SCCF1, SCCF2, SCCF3, 
and primary feline fibroblasts, which were used to reveal 
potential toxicity to normal cells. The IC50 was determined 
as the concentration in molarity in which the cell viability 
decreased by 50% as seen on the dose response curves 
in Figure 1. For additional insight into the achievability 
of plasma concentrations of the drugs in cats, the IC50 
values were compared to published values in human 
pharmacokinetic and toxicity studies. It is important to note 
that species differences in toxicity and pharmacokinetics 
exist. For example, cisplatin has been reported to 
be used at 50–60 mg/m2 in dogs for squamous cell 
carcinoma; however, cats receiving cisplatin at 60 mg/m2 
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are reported to become dyspneic and die within 48–96 
hours of administration [41]. Additionally, cats clear some 
drugs more slowly, such as acetaminophen, propofol, 
carprofen, and acetylsalicylic acid, than humans and dogs 
due to relative deficiencies in UDP-glucuronosyltransferase 
enzymes, N-acetyltransferase, and thiopurine 
methyltransferase; thus, drugs undergoing metabolism via 
conjugation may require dosage adjustments in comparison 
to humans and dogs to avoid toxicity in cats [42]. These 
differences, however, do not diminish the potential 
value of using FOSCC as a model for SCCHN as animal 
models of human disease have been demonstrated to 
provide translational insight into treatments for human 
diseases [43].
For all three FOSCC cell lines, actinomycin D had 
the lowest IC50, ranging from 0.6–1.3 nM and an IC50 of 
4 nM for the feline fibroblasts (Figure 1). With all three 
cell lines having roughly the same IC50 for actinomycin D, 
sensitivity to actinomycin D appears to be fairly consistent. 
In a pharmacokinetic study in children being treated 
with actinomycin D for a variety of tumors, the plasma 
concentration after 24 hours with variable dosing protocols 
was 1.8 mM which is higher than the IC50 value determined 
[44]. Dinaciclib had an IC50 ranging from 2.5–13 nM for 
the FOSCC cell lines and an IC50 of 32 nM for the feline 
fibroblasts (Figure 1). Although there is some variation 
in sensitivity to dinaciclib, the IC50 values are relatively 
similar across all three FOSCC cell lines. Pre-clinical 
Figure 1: Dose response curves of SCCF1, SCCF2, and SCCF3 cell lines as well as normal feline fibroblasts when 
treated with actinomycin D, dinaciclib, flavopiridol, and methotrexate. Graphs depict MTS assay results plotted as cell 
viability (%) against each of the drug concentrations. Error bars represent standard deviation. The table contains the corresponding IC50 
values in nanomolar concentration. 
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studies in humans suggest that dinaciclib is effective at 
greater than 50 nM which is achievable at the doses being 
used in Phase 2 studies; all of the IC50 values determined 
in this study are less than 50 nM [45]. Flavopiridol had an 
IC50 ranging from 32–250 nM for the FOSCC cell lines 
and an IC50 of 130 nM for the feline fibroblasts (Figure 1). 
There is some variation in IC50 values between the three 
FOSCC cell lines for flavopiridol, though the variation 
is within one order of magnitude. The IC50 value for the 
least susceptible cell line, however, is less than the steady-
state plasma concentration at the maximally tolerated 
dose reported in Phase I trials [46]. Methotrexate had an 
IC50 ranging from 64–320 nM for the FOSCC cell lines; 
however, an IC50 value was not able to be determined for 
the feline fibroblasts (Figure 1). There is some variation 
in IC50 values between the three FOSCC cell lines for 
methotrexate, though the variation is less than an order of 
magnitude. For the least susceptible cell line, the IC50 value 
is less than 1 μM, the concentration currently considered 
the maximum concentration 42 hours after the start of a 
high dose methotrexate infusion to avoid toxicity in people. 
While the differences are not greater than an order of 
magnitude, it is interesting that SCCF3 was relatively more 
sensitive to dinaciclib and less sensitive to flavopiridol and 
methotrexate than both SCCF1 and SCCF2 (Figure 1). One 
potential explanation for this is differences in molecular 
mechanisms driving cellular proliferation as well as 
differences in metabolic pathways. As a whole, all of the 
drugs have an IC50 value in the low nanomolar range for 
at least two of the cell lines (Figure 1), supporting the 
proposed hypothesis. While in vivo studies evaluating 
the pharmacokinetics of these drugs in cats are necessary, 
the results of this study suggest that effective concentrations 
may be achievable in the plasma.
By using feline fibroblasts as a surrogate for non-
neoplastic tissue, comparisons of IC50 values between the 
cell lines and fibroblasts may provide potential insight 
into potential concerns about toxicity to the patient. 
It is important to note that using feline fibroblasts as a 
surrogate for normal tissue may not be indicative of tissue 
specific toxicities and further studies into the potential 
toxic effects of these drugs are warranted; however, the 
use of feline fibroblasts provides an initial insight into 
toxic effects. Further studies into potential toxic effects 
of these drugs are warranted. Actinomycin D had an IC50 
value for the feline fibroblasts about 7 times greater than 
the SCCF1 and SCCF2 cell lines and about 3 times greater 
than SCCF3 cell line (Figure 1). Though the IC50 value for 
actinomycin D for the fibroblasts was relatively low, there 
was a fairly large difference in IC50 values between some 
of the neoplastic cell lines and the fibroblasts; thus, a very 
low dose may potentially be given to target neoplastic cells 
while minimalizing effects on normal tissue. Dinaciclib 
has an IC50 value for fibroblasts greater than for any of 
the FOSCC cell lines though the difference is greatest for 
SCCF2 and SCCF3, with the IC50 8 times and 13 times 
greater for the feline fibroblasts, respectively. There may 
be concerns about toxicity for treating some tumors; 
however, there may be subsets of FOSCC that are more 
sensitive to dinaciclib, especially tumors most similar 
to SCCF3. For the more susceptible subset, dinaciclib 
may potentially be a promising treatment option. Further 
investigation into biomarkers to identify such tumors 
would be warranted; additionally, the development of a 
FOSCC drug screen on patient samples may potentially 
be able to identify useful drugs specific to the patient’s 
disease. Flavopiridol had an IC50 value somewhat greater 
for the feline fibroblasts than SCCF1 and SCCF2 though 
the difference was not very large, only about 4 and 3 
times greater, respectively (Figure 1). SCCF3, however, 
had an IC50 value nearly double that of the IC50 for the 
fibroblasts. With data from all three cell lines taken into 
account, flavopiridol may present concerns about toxic 
effects in normal tissue, and, in some instances, normal 
tissue may be more susceptible to the drug than neoplastic 
cells. Nevertheless, flavopiridol may have potential use 
in some FOSCC patients if developed into an implant for 
local distribution; similar applications have been used with 
cisplatin [47]. Methotrexate could not have an IC50 value 
determined for the fibroblasts due to high concentration 
of drugs that would be required (Figure 1). Similar to 
actinomycin D, there are fewer concerns about toxicity to 
normal tissue based on the large difference in IC50 values 
between the fibroblasts and the neoplastic cell lines. 
Performing in vivo studies pertaining to toxicity 
as well as pharmacodynamics and pharmacokinetics in 
cats would add further insight into the potential safety 
of the selected drugs as in vitro analysis does not always 
represent in vivo responses. Until such studies are 
performed, the comparisons made to pharmacological 
studies in humans provide insight into whether or not the 
determined IC50 values may be achievable. 
Effects of actinomycin D, dinaciclib, flavopiridol, 
and methotrexate on cell cycle progression
To gain further insight into the potential mechanism 
of action of the drugs, a cell cycle assay using propidium 
iodide was used to determine the effects of actinomycin 
D, dinaciclib, flavopiridol, and methotrexate on each 
FOSCC cell line on cell cycle progression (Figure 2). 
SCCF1, SCCF2, and SCCF3 cells were treated with either 
actinomycin D, dinaciclib, flavopiridol, or methotrexate for 
twenty-four hours. Cells were then distributed into G1, S, and 
G2 subpopulations with data from a representative experiment 
displayed (Figure 2 and Supplementary Figure 1). 
For SCCF1, actinomycin D and dinaciclib treatment 
did not greatly alter cell cycle progression (Figure 2A). 
As the mechanism of action for actinomycin D is through 
inhibiting RNA synthesis, minimal effect on cell cycle 
progression is as expected [48, 49]. Flavopiridol had 
a large shift of cells into G2 for SCCF1, suggesting that 
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these drugs may arrest cells in G2 and prevent progression 
into M phase, potentially by affecting CDK involved in 
late G2 or M phase initiation such as CDK1 (Figure 2A) 
[48]. Methotrexate also had a large shift of cells into 
G2 for SCCF1, indicative of G2 arrest (Figure 2A). 
Methotrexate has been previously reported to cause late 
S/G2 arrest in lymphocytes [50]. Actinomycin D did not 
greatly alter cell cycle progression for SCCF2 (Figure 2B). 
Dinaciclib and flavopiridol had a similar effect on cell 
progression in SCCF2 cells by increasing the proportion of 
cells in G2 phase (Figure 2B); this may occur through a 
similar mechanism proposed for SCCF1 for flavopiridol. 
Methotrexate had a large shift of cells into G1 (Figure 2B). 
The methotrexate findings are similar to the G1 and S 
arrest described in human colorectal adenocarcinoma C85 
cells when treated with methotrexate; it proposed that the 
cell cycle arrest was due to DNA damage accumulating, 
not DNA synthesis inhibition [51]. Similar to SCCF1 and 
SCCF2, actinomycin D had no significant effect on cell 
cycle progression for SCCF3 (Figure 2C). Dinaciclib and 
flavopiridol caused a large shift of cells into G1 for SCCF3 
(Figure 2C). Dinaciclib and flavopiridol may arrest cells 
in G1 and prevent progression into S phase, potentially by 
affecting CDK involved in late G1 or S phase initiation 
such as CDK2 for the CDK inhibitors [48]. Methotrexate 
similarly cause a large increase of cells into G1 for SCCF3; 
this is most likely similar to the mechanism provided for 
SCCF2 (Figure 2C). While cell cycle arrest is consistently 
noted for flavopiridol and methotrexate across all cell 
lines and for dincaciclib for two of the three cell lines, the 
effects of the drugs vary depending on the cell line. The 
mechanism behind this is not well understood. Potential 
explanations include differences in tumorigenesis and the 
factors driving cellular proliferation. Further investigation 
into these changes is warranted in future studies [52, 49]. 
It is interesting to note that flavopiridol has demonstrated 
growth suppression of a tumorigenic head and neck 
squamous cell carcinoma cell line in vitro which may 
further support the finding that flavopiridol alters cell cycle 
progression [52]. 
Depending on the stage of the cell cycle in which the 
drugs inhibit cell cycle progression, radiosensitivity may 
be altered [53]. Shifts into G1 and G2 phases were noted 
depending on the drug and cell line (Figure 2A–2C). The shift 
of cells into G1 or G2 phase may increase the radiosensitivity 
of the cell lines as cells in G1 are more sensitive to radiation 
than cells in S phase, and cells are most radiosensitive in 
G2/M [54]. Thus, inhibition of cell cycle progression has the 
potential to radiosensitize the FOSCC cell lines, increasing 
the effectiveness of radiation therapy; however, further 
investigation is needed to support these claims. 
CDK inhibitors induced apoptosis at higher 
concentrations across all cell lines
To determine the ability of the drugs of interest 
to induce apoptosis in the FOSCC cell lines,  the effect 
of drugs on activity of caspase-3/7 was measured using 
a luminescence assay. Caspase-3/7 are executioner 
caspases that cleave many substrates leading to apoptosis 
[55]. Thus, measuring the activity of caspase-3/7 can act 
as a surrogate for determining the ability of the drugs of 
interest to induce apoptosis. SCCF1, SCCF2, SCCF3, and 
feline fibroblasts were treated with two concentrations of 
actinomycin D, dinaciclib, flavopiridol, and methotrexate 
for 24 hours. The concentrations used were approximately 
the IC50 value and ten times the IC50 value. Caspase-3/7 
activity was greatly increased for dinaciclib and 
flavopiridol at 50 nM and 1 μM, respectively (Figure 3). 
Actinomycin D and methotrexate did not induce apoptosis 
at the low and high concentrations used (Figure 3). 
Potential explanations include the following: actinomycin 
D and methotrexate require more than 24 hours to cause 
cell death or higher concentrations are needed to induce 
apoptosis within the time frame used. Dinaciclib and 
flavopiridol did not increase caspase-3/7 activity at 5 nM 
and 100 nM, respectively, across all cell lines; however, 
dinaciclib and flavopiridol increased caspase-3/7 activity 
when used at 50 nM and 1 µM, respectively (Figure 3). 
Thus, at higher concentrations, dinaciclib and flavopiridol 
induced apoptosis of all of the FOSCC cell lines. Higher 
concentrations than the IC50 value may be needed 
because the apoptosis assay was at twenty-four hours 
while the inhibitory concentrations were determined 
after treatment for seventy-two hours. The data suggests 
that the ability of dinaciclib and flavopiridol to induce 
apoptosis is concentration dependent. One of the goals of 
chemotherapy for neoplasms is to induce apoptosis due to 
the correlation between apoptosis and therapeutic response 
[56]. Thus, the ability of dinaciclib and flavopiridol to 
induce apoptosis in all three FOSCC cell lines supports the 
potential of these drugs to be used as chemotherapeutics 
for FOSCC to target the bulk of the tumor.
MATERIALS AND METHODS
Culture of FOSCC cell lines SCCF1, SCCF2, 
SCCF3, and feline fibroblasts
SCCF1, SCCF2, and SCCF3 cell lines were cultured 
in DMEM supplemented with 10% fetal bovine serum 
(FBS), 1% antibiotic-antimycotic (Anti-Anti (100×); 
Gibco), 0.1% gentamicin (Gibco) as well as epidermal 
growth factor (EGF) at 10 ng/mL and cholera toxin at 0.1 nM 
(referred to as complete media). Feline fibroblasts were 
cultured in DMEM supplemented with 10% FBS, 1% 
antibiotic-antimycotic, and 0.1% gentamicin (referred to 
as fibroblast media).
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Figure 2: Cell cycle analysis of SCCF1, SCCF2, and SCCF3 cell lines after treatment with actinomycin D, dinaciclib, 
flavopiridol, and methotrexate. Graphs depict percent of cells in G1 phase, S phase, and G2 for the following treatments: control, 
actinomycin D, dinaciclib, flavopiridol, and methotrexate. (A–C) represent SCCF1, SCCF2, and SCCF3, respectively. Error bars represent 
standard deviation.
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High throughput screening of FOSCC Cells 
Cell lines SCCF1, SCCF2, and SCCF3 as well 
as feline fibroblasts derived from skin were plated in a 
384-well plate at 5,000 cells per well. A total of 1,952 
compounds comprised of the Prestwick (Prestwick 
Chemical), Approved Oncology Drugs Set V (NCI 
Developmental Therapeutics Program), and Published 
Kinase Inhibitor Set (PKIS, Structural Genomics Center, 
University of North Carolina at Chapel Hill) libraries 
were delivered to cells using a Biomek FX Workstation 
liquid handling system (Beckman Coulter) using a single 
concentration of 1 µM. After 48 hours of incubation, 
CellTiter-Glo Cell Viability (Promega, Madison, WI) 
reagent was added and luminescence signal was read using 
a Synergy Neo (BioTek) detection platform. 
Dose response confirmation assay of selected 
compounds 
SCCF1, SCCF2, and SCCF3 cell lines were seeded 
into 384-well plates at 5,000 cells per well concentration. 
As cells attached to the bottom of the plate after four 
hours, selected compounds were added at eight different 
concentrations with a three-fold difference used and a 
maximum concentration of 10 µM. Cell viability was 
measured after 48 hours of incubation as described 
previously. Using the calculated percentage of viability 
at each concentration, pIC50 of each compound was 
calculated using GRETL software within MScreen, 
an HTS data storage and analysis system (Center for 
Chemical Genomics, University of Michigan) [59].
Cell viability assay of confirmed hits 
Cell viability assays were performed using SCCF1, 
SCCF2, and SCCF3 cell lines as well as on feline 
fibroblasts, which were used as surrogates for normal 
tissue response to the drugs. The HTS was performed at 
only one concentration; thus, a dose response curve using a 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was used to 
determine the IC50 of the drugs of interest. The experiments 
were performed in triplicate. Cells were plated at a density 
of 3,000 cells per well in a 96 well plate and then incubated 
for twenty-four hours. The next day, the media was 
removed and replaced with complete media or fibroblast 
media containing either actinomycin D, dinaciclib, 
Figure 3: Apoptosis assay for SCCF1, SCCF2, SCCF3, and feline fibroblasts after treatment with actinomycin D, 
dinaciclib, flavopiridol, and methotrexate for 24 hours. Graph depicts fold change in caspase-3/7 activity after treatment with 
0.1% DMSO, actinomycin D at 0.1 and 1 nM, dinaciclib at 5 and 50 nM, flavopiridol at 100 nM and 1 µM, methotrexate at 100 nM and 
1 µM, and staurosporine at 1 µM. Error bars represent standard deviation.
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flavopiridol, or methotrexate. The following concentrations 
were used for actinomycin D: 1 pM, 10 pM, 100 pM, 1 
nM, 10 nM, and 100 nM. The following concentrations 
were used for dinaciclib, flavopiridol, and methotrexate: 
0.1 nm, 1 nm, 10 nm, 100 nm, 1 μm, and 10 μm. Drugs 
were dissolved in DMSO with the final concentration 
of DMSO in all media applied to cells equaling 1%. A 
vehicle-only treated control consisting of either complete 
media or fibroblast media with 1% DMSO was used. Plates 
were then incubated for 72 hours. An MTS assay was then 
performed using CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega, Madison, WI), which was 
incubated for three hours [60]. An MTS assay detects a 
colored, soluble formazan dye produced by mitrochondrial 
metabolism of the tetrazolium salt; thus, the detected level 
of absorbance is proportional to the number of living cells 
[36]. The results were then determined using EnVision 
Multilabel Plate Reader (PerkinElmer). The calculated 
percentage at each (log10) drug concentration was plotted 
using GraphPad Prism 6 software nonlinear regression 
curve fitting (GraphPad Software) to calculate the IC50 
value of each compound.
Propidium iodide cell cycle analysis
Cell cycle inhibition was analyzed using propidium 
iodide DNA labelling and flow cytometry as a means to gain 
insight into a potential mechanism of action [61]. For each 
of the SCCF1, SCCF2, and SCCF3 cell lines, 5 × 105 cells 
were added to five wells on a six well plate for each cell 
line. Plates were then incubated overnight. The media 
was then removed and replaced with complete media 
with either 0.1% DMSO, 1 nM actinomycin D, 50 nM 
dinaciclib, 500 nM flavopiridol, or 5 µM methotrexate. 
Plates were incubated for 24 hours with the drugs. Cells 
were then fixed with 70% ethanol and labeled with 
propidium iodide, and RNAse A was added. Samples were 
then incubated at 4° C until analysis by flow cytometry. 
For analysis of DNA content, the flow cytometer BD LSR 
II (BD Bioscience) was used, and, for data interpretation, 
MOdFit LT V4.1.7 software (VSH) with auto fit and auto 
linearity settings was used. The experiment was performed 
in triplicate. Statistical analysis was done using Tukey’s 
multiple comparison two-way ANOVA test.
Apoptosis assay
A luminescent caspase-3/7 assay (Caspase-Glo® 3/7 
Assay, Promega) was performed to determine the ability 
of the drugs to induce apoptosis in vitro [62]. For each 
of the SCCF1, SCCF2, and SCCF3 cell lines as well as 
the feline fibroblasts, 10,000 cells were plated in a 96 
well plate. The cells were then incubated until the cells 
adhered. The media was then removed and replaced with 
either 0.1% DMSO, 1 μM staurosporine, actinomycin D at 
0.1 nM or 1 nM, dinaciclib at 5 nM or 50 nM, flavopiridol 
at 100 nM or 1 μM, or methotrexate at 100 nM or 1 μM. 
Staurosporine, a bacterial alkaloid, was used as a positive 
control as it is used commonly as an inducer of apoptosis 
[63]. Cell were then incubated for 24 hours. Caspase 
reagent from Caspase-Glo® (Promega) was added per well 
for 30 minutes. Plates were then read using EnVision Plate 
Reader (PerkinElmer). The experiment was performed in 
triplicate. Data were statistically analyzed using a multiple 
comparison two-way ANOVA test.
CONCLUSIONS
There are multiple possible directions for future 
studies. Experiments using combinations of the drugs of 
interest could be performed to evaluate any synergistic 
effect between the drugs and to explore alternative 
protocols using lower doses of each drug. Determining 
the expression of multiple CDK for SCCF1, SCCF2, 
and SCCF3, as well as with a surrogate for epithelial 
tissue, would be beneficial by providing insight into 
the tumorigenesis of these cell lines which would then 
potentially help further explain the mechanism of action 
of the drugs. CDK expression could be determined at 
the transcription level as well as the protein level. In 
addition, testing the ability of the drugs to target putative 
stem cell fractions as well as the ability of the drugs to 
increase the radiosensitivity of the cell lines needs to be 
performed. Performing studies investigating the safety 
as well as pharmacokinetics and pharmacodynamics of 
the drugs of interest in cats are important to optimize a 
protocol of treatment. 
Overall, FOSCC are highly aggressive and 
invasive tumors in cats [20]. Life expectancy is poor 
despite treatment, with average life expectancy after 
clinical presentation ranging from two to ten months 
despite of treatment [22]. This study demonstrates 
that actinomycin D, dinaciclib, flavopiridol, and 
methotrexate are promising therapeutics for FOSCC. 
All four have IC50 values in the low nanomolar range 
for all cell lines studied: SCCF1, SCCF2, and SCCF3. 
The IC50 concentrations determined may be achievable 
in the plasma in cats; however, the safety of these drugs 
as well as investigations into their pharmacokinetics 
and pharmacodynamics are warranted. The inhibitory 
concentrations determined are, however, lower than 
the achievable and tolerated doses for humans, further 
strengthening the possibility for successful use in cats.
[44–46, 57] There does appear to be variability in the 
sensitivity of the cell lines to the drugs. Intra- and inter-
tumor heterogeneity are a normal characteristics of 
tumors and may explain the differences in susceptibility 
[58]. The data suggests that the CDK inhibitors may 
inhibit cell growth by preventing progression through 
different stages of the cell cycle depending on the cell 
line. Methotrexate also alters cell cycle progression 
depending on the cell line. The CDK inhibitors induced 
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apoptosis in all cell lines tested. Thus, initial results 
suggest that the selected drugs are potential candidates 
for developing novel chemotherapeutic approaches to 
feline FOSCC. The use of methotrexate for FOSCC is 
further supported by the use of methotrexate in SCCHN 
[13]. In addition to the potential impact on feline health, 
these studies may ultimately provide translational 
insight into SCCHN in humans which are equally 
aggressive cancers in need of improved therapies [4].
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